Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 4/20 | 0.49 |
| ▸ | JAK2 | O60674 | 3/20 | 0.49 |
| ▸ | JAK1 | P23458 | 3/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | TTK | P33981 | 1/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 5/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | PAK4 | O96013 | 3/20 | 0.38 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4909551 | 0.91 | JAK2 (0.51) | BRD4JAK2JAK1TGFBR1TTK | |
| SCHEMBL4914224 | 0.91 | JAK2 (0.51) | BRD4JAK2JAK1TGFBR1TTK | |
| SCHEMBL4920915 | 0.86 | JAK2 (0.50) | BRD4JAK2JAK1TGFBR1TTK | |
| SCHEMBL4917672 | 0.85 | PTK2 (0.39) | BRD4JAK2JAK1PTK2JAK3 | |
| SCHEMBL4919419 | 0.82 | JAK2 (0.46) | BRD4JAK2JAK1TGFBR1PTK2 | |
| SCHEMBL4918495 | 0.79 | JAK2 (0.46) | BRD4JAK2JAK1TGFBR1TTK | |
| SCHEMBL4914873 | 0.77 | PAK4 (0.63) | BRD4JAK2JAK3PAK4 | |
| SCHEMBL4917648 | 0.76 | PTK2 (0.40) | BRD4JAK2JAK1PTK2JAK3 | |
| SCHEMBL4916456 | 0.76 | PTK2 (0.40) | BRD4JAK2JAK1PTK2JAK3 | |
| SCHEMBL4650409 | 0.76 | PTK2 (0.51) | BRD4JAK2JAK1TGFBR1PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261973-A1 | Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors | NOVARTIS AG (CH) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261973-A1 | Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors | GRK4, JAK2, ALK | BRD4 93/4885JAK2 2/4885JAK1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.